IngredientsThe term trisaccharide does not refer to a single compound but to a structural class of carbohydrates. A trisaccharide is a type of oligosaccharide that consists of three monosaccharide units (sugar molecules) linked together by glycosidic bonds. These sugar units can be the same or different, and trisaccharides are found in various plants and foods, serving a variety of functions such as energy storage or acting as sweeteners. Because several biologically distinct trisaccharides are researched, used, or sold in supplement contexts, a scientifically complete account must address the principal members individually. The three most scientifically studied trisaccharides with documented roles in human nutrition and supplementation are:
A fourth compound, lacto-sucrose, is also briefly noted. The article proceeds by first describing chemical identity and natural sources, followed by historical and traditional use contexts, then biochemical mechanisms, clinical evidence organized by health area, reported dosages, and safety considerations.
Raffinose is a trisaccharide that contains fructofuranoside and galactopyranoside rings connected to a central glucopyranoside. More precisely, raffinose is a tri-saccharide composed of galactose, glucose, and fructose — specifically α-d-galactose, α-d-glucose, and β-d-fructose. Its full systematic chemical name is α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→2)-β-D-fructofuranoside. Structurally, raffinose can be understood as a sucrose molecule with an additional α-galactose unit attached via an α-1,6-glycosidic bond.
Raffinose family oligosaccharides (RFOs) are soluble carbohydrates ranked next to sucrose in their distribution in higher plants. The most common RFOs in plants are raffinose (trisaccharide), stachyose (tetrasaccharide), and verbascose (pentasaccharide). Raffinose, stachyose, and verbascose are the three types of raffinose family oligosaccharides that have been extensively used as medicine, cosmetic, and food additives.
In terms of food distribution, beans, lentils, chickpeas, and other legumes contain the highest concentrations of raffinose among food sources; soybeans are especially notable, with raffinose comprising up to 1.1% of their dry weight. Cruciferous vegetables like cabbage, Brussels sprouts, broccoli, and cauliflower contain moderate amounts of raffinose. The scientific study of raffinose dates back to at least 1877, when French chemist D. Loiseau isolated it from sugar beet molasses; in 1886, British chemist C. O'Sullivan described extracting and crystallizing the compound from ground barley. Fructo-oligosaccharides (FOS), close relatives of raffinose in the broader oligosaccharide family, may be derived from the blue agave plant as well as a variety of fruits and vegetables including bananas, onions, chicory root, garlic, asparagus, Jerusalem artichoke, jicama, and leeks, and are also present in certain grains and cereals such as wheat and barley.
The most abundant HMO in the majority of mothers' breast milk is 2′-fucosyllactose (2′-FL), a trisaccharide consisting of glucose, galactose, and fucose. Chemically, 2′-fucosyllactose is galactose-beta-1,4-glucose with a fucose-alpha-1,2 linked to the galactose residue. It is therefore a fucosylated lactose molecule. Human milk oligosaccharides (HMOs) are the third most abundant solid component in human milk after lactose and lipids. Of the more than 100 different HMOs that have been identified in human milk, less than 50 are present in significant amounts. The first comprehensive analysis of HMOs from human milk in approximately 400 lactating women from 10 countries found that 85% of human milk samples had detectable 2′-FL at concentrations of 0.06–4.65 g 2′-FL/L.
2′-FL has been synthesized and shown to be structurally identical to the 2′-FL found in human milk. 2′-FL HMO is now available in some commercial infant formulas. The synthesis patent application (US 9012625) notes that one of the most important human milk oligosaccharides is 2′-O-fucosyllactose, and several biological roles have been suggested, including prebiotic, antibacterial, antiviral, immune system enhancing, and brain development-enhancing effects, making it an attractive target for large-scale production for nutritional and therapeutic industries.
Maltotriose is a trisaccharide composed of three α-d-glucose units derived from enzymatic digestion. It arises naturally from the hydrolysis of starch and glycogen by α-amylases and is an intermediate in starch digestion. Malto-oligosaccharide (MOS) preparations analyzed in research contexts consist of 21.74% maltotriose, 18.84% maltotetraose, and 11.76% maltopentaose produced by amylase (HATT). Maltotriose also arises in fermentation contexts: lactic acid bacteria with dextranase hydrolytic enzymatic activity can produce another trisaccharide, maltotriose.
The trisaccharide panose, which is the isomer of maltotriose having one α-D-Glc (1→6) and the other α-D-Glc (1→4) glycosidic bond, is considered an isomalto-oligosaccharide (IMO) and can be digested by mucosal α-D-glucosidase. The co-addition of maltose and sucrose in lactic acid fermentation resulted in the production of panose (up to 37.53 mM), an oligosaccharide known for its prebiotic effect.
Lacto-sucrose is a trisaccharide oligosaccharide composed of galactose, glucose, and fructose that occurs naturally at low concentration in yogurt when both sucrose and lactose sugars are present together in the milk, and is commercially produced enzymatically using both sucrose and lactose as substrates.
Raffinose has not historically been extracted and used as an isolate in traditional medicine. Its historical significance lies in the prolonged dietary consumption of raffinose-containing legumes across global food cultures. Lentils, chickpeas, beans, peas, and soybeans — all major sources of raffinose — constitute staple foods in South Asian, Middle Eastern, Mediterranean, East Asian, and sub-Saharan African cuisines dating back thousands of years. The presence of raffinose saccharides in legumes restricts their use in human diets despite many of these species being otherwise excellent sources of protein and soluble fiber.
Traditional food preparation practices reflect an empirical, pre-scientific understanding of raffinose's digestive effects. Traditional cooking methods often include soaking beans before cooking — a process that can reduce raffinose content. Many strategies used for the improvement of the nutritional quality of lentils and beans have proven successful in decreasing the concentration of RFOs, such as dehulling, germination, soaking (in alcohol or water), various heat-treatments (boiling, autoclaving, microwave cooking, extrusion), enzymatic treatment, irradiation, or fermentation. These practices were developed empirically to reduce gas-producing fermentation in the gut, without knowledge of the underlying chemistry.
The isolation of raffinose as a chemical entity began in 19th-century European chemistry. The study of raffinose goes back to at least 1877, when French chemist D. Loiseau isolated it from sugar beet molasses; in 1886, British chemist C. O'Sullivan described how he extracted ground barley with alcohol and worked up the resulting syrup to crystallize the product, which he identified as the "raffinose of Loiseau." These early isolations were analytical achievements rather than therapeutic applications.
While the chemical identity of 2′-FL was not established until the 20th century, human breast milk has been recognized as the optimal infant food in virtually all cultures throughout recorded history. The protective and immune-supporting properties attributed to breast milk in various traditions align broadly with what is now understood to be the bioactivity of HMOs including 2′-FL. Previously, human milk has been the only source for significant levels of HMOs. Preclinical research has demonstrated that HMOs and specifically 2′-FL are more than a prebiotic and have multiple functions including immune, gut, and cognition benefits; previously, human milk was the only source for significant levels of HMOs.
The biological behavior of all dietary trisaccharides is governed primarily by the nature and position of their glycosidic bonds. Functional oligosaccharides (FOSS) are low molecular weight non-digestible short chain carbohydrate polymers linked together by glycosidic bonds. The key structural feature of raffinose that determines its physiological fate is the α-1,6-galactosidic bond. This molecular arrangement is what makes raffinose resistant to human digestive enzymes, as our bodies lack the necessary α-galactosidase enzyme needed to break the bonds between these sugar molecules. Humans and animals do not produce an α-galactosidase enzyme to synthesize and digest the RFOs in the intestine; therefore, RFOs escape the digestion process and get utilized by the gut microbes (bacteria).
Raffinose family oligosaccharides cannot be digested in the upper gastrointestinal tract because of the absence of the enzyme α-galactosidase, but can be utilized by bifidobacteria and lactobacilli, and produce short-chain fatty acids. Being non-digestible, FOSS escape the digestion in the upper gut and move as such to the colon where they are fermented to lactate, short chain fatty acids (SCFA) and carbon dioxide, hence promoting the growth of the prebiotic bacteria mainly Bifidobacteria and inhibiting the growth of harmful bacteria, thus imparting several health benefits such as prevention from colon cancer, constipation, improved gut health, mineral absorption, glucose tolerance, etc.
These compounds are capable of surviving acidic and enzymatic digestion in the small intestine and can thus be fermented by probiotics that reside in the colon/cecum. The fermentation of prebiotics by probiotics leads to the production of short-chain fatty acids, which lower intestinal pH, inhibiting the growth of potentially pathogenic bacterial populations and improving the absorption of minerals such as iron.
RFOs act as reserve carbohydrates and are reported as compatible solutes that function like antioxidants, are a component of carbon partitioning strategies, and may act as stress signals. RFOs can react with reactive oxygen species (ROS) using mechanisms similar to fructans, resulting in the formation of sugar-phenol compounds, higher DP-neutral carbohydrates, or phenolics — a mechanism that can protect against ROS-mediated lipid peroxidation in the tonoplast.
Raffinose family oligosaccharides avert the adhesion and colonization by enteric pathogens and add nutrition metabolites for a healthy immune system. For 2′-FL, HMOs may support immune function development and provide protection against infectious diseases directly through the interaction of the gut epithelial cells or indirectly through the modulation of the gut microbiota, including the stimulation of the bifidobacteria.
The same fermentative mechanism that confers prebiotic benefit also carries the risk of gas production. RFOs escape the digestion process and get utilized by the gut microbes (bacteria) to synthesize by-products like hydrogen (H₂), carbon dioxide (CO₂), and methane (CH₄); thus, RFOs primarily cause flatulence in humans and animals.
Raffinose / RFOs: The prebiotic classification of raffinose is supported by in vitro and animal data, with some corroboration from human studies. Raffinose can increase the growth of lactic acid bacteria, suppress the growth of pathogenic bacteria, increase short-chain fatty acids (SCFA), reduce constipation, inhibit the formation of putrefactive compounds from protein, and reduce the risk of cardiovascular diseases. In humans, RFOs have beneficial effects in the large intestine and have shown prebiotic potential by promoting the growth of beneficial bacteria, reducing pathogens and putrefactive bacteria present in the colon.
In an in vitro study of anti-inflammatory effects, individually, the prebiotics raffinose, stachyose, verbascose, oligomate 55NP, and beta-glucan decreased the secretion of IL-8 from stimulated HT-29 cells, as compared to stimulated controls. Synbiotic combinations of the tested probiotics with raffinose, soy extract, or oligomate 55NP significantly reduced the IL-8 production in stimulated HT-29 cells, as compared to probiotics alone. This is cell-line (in vitro) evidence and cannot be directly extrapolated to human clinical outcomes.
Raffinose family oligosaccharides were successfully extracted from Kabuli and Desi chickpeas using ethanol and hot water treatments. Chickpea-RFOs were found to have antioxidant activity and anti-food-borne pathogen properties, and prebiotic chickpea-RFOs could enhance probiotic growth and adherence to a human colon cancer cell line (HCT-116). This again represents laboratory-based (in vitro) evidence.
Maltotriose / Malto-oligosaccharides: A study measured the proliferative activity of malto-oligosaccharide (MOS) as a prebiotic against Bifidobacteria, resistance to digestion in vitro, and changes during in vitro fermentation by human fecal microorganisms. When 1% of MOS was added to a modified PYF medium as the carbon source, proliferation of Bifidobacterium breve was increased significantly. The 2% addition of MOS reduced intestinal pathobiont microorganisms and increased commensal microorganisms including the Bifidobacterium genus; collectively, MOS produced by amylase increased SCFA production and enhanced the growth of beneficial bacteria during in vitro fermentation by human fecal microbiota. This evidence is in vitro and therefore preliminary.
Overall prebiotic evidence quality: A 2022 systematic review of randomized controlled trials on prebiotics broadly concluded that an analysis of 22 randomized controlled trials from the past decade confirmed that prebiotic supplementation consistently increased the abundance of beneficial bacteria (e.g., Bifidobacterium and Lactobacillus) and SCFA production, with changes associated with significant clinical improvements including enhanced stool frequency and consistency, strengthened intestinal barrier function, and modulated immune responses. However, significant inter-individual variability in response was evident, and study designs showed notable heterogeneity in prebiotic type, dosage, and duration. Evidence specifically for raffinose as a stand-alone supplement in humans remains limited compared to more extensively studied prebiotics such as inulin and FOS.
RFOs: RFOs show health benefits such as antioxidative activity, intestinal homeostasis, healing properties, enhanced immunity, and anticancer activity. These claims are primarily supported by in vitro and animal models; large-scale human clinical trials specifically testing immune outcomes with isolated raffinose are not yet established in the reviewed literature.
2′-Fucosyllactose: Clinical experiences demonstrated that 2′-FL being added to infant formula was safe, well-tolerated, and absorbed and excreted with similar efficiency to 2′-FL in human milk; further, infants fed formula with 2′-FL had immune benefits, fewer parent-reported respiratory infections, and improved symptoms of formula intolerance. HMOs may support immune function development and provide protection against infectious diseases directly through the interaction of the gut epithelial cells or indirectly through the modulation of the gut microbiota, including stimulation of the bifidobacteria.
This area has the most robust clinical evidence for a specific trisaccharide. The first clinical study to investigate 2′-FL in infant formula was a prospective, randomized, controlled, growth, and tolerance study conducted in healthy term infants, with 420 infants enrolled by 5 days of life. The three study formulas included a control formula without added HMO and two study formulas differing in the amount of 2′-FL: 0.2 g 2′-FL/L versus 1.0 g 2′-FL/L.
A separate randomized controlled trial evaluated feeding tolerance of 2′-FL in a 100% whey, partially hydrolyzed infant formula with the probiotic Bifidobacterium animalis ssp. lactis strain Bb12, as compared with the same formula without 2′-FL, in healthy infants enrolled at 2 weeks of age (±5 days), with the primary outcome of tolerance assessed using the Infant Gastrointestinal Symptom Questionnaire after 6 weeks of feeding. Seventy-nine infants were enrolled and 63 completed the study per protocol (30 Test, 33 Control); Infant Gastrointestinal Symptom Questionnaire scores were similar between groups (Test 20.9 ± 4.8, Control 20.7 ± 4.3, P = .82), confirming that partially hydrolyzed infant formula with 2′-FL and B. lactis is tolerated well.
A further randomized clinical trial examined the effect of adding 2′-FL to an infant formula already containing prebiotic galacto-oligosaccharides (GOSs) and fructo-oligosaccharides (FOSs) on the gut microbiome of healthy formula-fed infants, enrolling infants into an HMO experimental group (n=29), a GOS/FOS control group (n=30), and an exclusively breastfed reference group (n=28).
Reviewing the collective evidence, a 2018 narrative review concluded that the limited clinical data suggest that the addition of HMOs to infant formula seems to be safe and well tolerated, inducing normal growth and suggesting a trend towards health benefits. The review also called for more prospective, randomized trials in infants to evaluate the clinical benefit of supplementing infant formula with HMOs. Overall, the evidence quality for 2′-FL in infant formula is moderate — supported by multiple RCTs but with relatively small sample sizes and limited follow-up durations.
RFOs show health benefits such as antioxidative activity, intestinal homeostasis, healing property, enhanced immunity, and anticancer activity. These metabolites in high concentration can stabilize the enzymes involved in ROS detoxification and also exhibit higher second-order rate constants for detoxification compared to common antioxidants; RFOs can react with ROS using mechanisms similar to fructans. Evidence for antioxidant activity in humans is currently preclinical or mechanistic; no human intervention trials specifically measuring oxidative biomarker outcomes for isolated raffinose were identified in the reviewed literature.
Many other biological activities of RFOs have been reported apart from the prebiotic potential, such as anti-allergic effects, anti-obesity, anti-diabetic, and prevention of non-alcoholic fatty liver disease through inhibition of lipid accumulation, reduction of fecal ammonia and indole, cryoprotection, and inhibition of Pseudomonas aeruginosa biofilm formation. RFOs have beneficial effects thanks to their prebiotic activity and other biological functions such as anti-allergic, anti-obesity, and anti-diabetic effects, and the prevention of non-alcoholic fatty liver disease.
These claimed metabolic benefits are cited with references to animal and in vitro studies in the source literature reviewed. The extract from lupin seeds had positive effects on the survival of probiotic cultures in dairy products, and RFOs isolated from the novel plant Rehmannia glutinosa were used as food ingredients to prevent ROS-related liver damage. RFOs also reduced the severity of colon inflammation in mice. Evidence for these metabolic properties in humans is at an early, exploratory stage, with no large clinical trials identified in this review.
One study investigated the effectiveness of stachyose and raffinose — prebiotics present in staple food crops widely consumed in regions where dietary iron deficiency is a health concern — with the hypothesis that these prebiotics would improve iron status, intestinal functionality, and increase health-promoting bacterial populations in vivo. The fermentation of prebiotics by probiotics leads to the production of short-chain fatty acids, which lower intestinal pH, inhibiting the growth of potentially pathogenic bacterial populations and improving the absorption of minerals such as iron. This evidence derives from an animal model (avian intra-amniotic administration) and cannot be directly translated to human supplementation.
Prebiotic-associated changes in microbiota are associated with significant clinical improvements including enhanced stool frequency and consistency, strengthened intestinal barrier function, and modulated immune responses, with benefits documented in healthy individuals, children, the elderly, and those with conditions such as constipation, metabolic syndrome, and antibiotic-associated dysbiosis. These effects are established for the broader prebiotic category; evidence specific to raffinose in human trials is more limited.
Regarding galacto-oligosaccharides (GOS) broadly — which include the RFO sub-class — the digestive enzyme supplement alpha-galactosidase, which helps the breakdown of GOS, may reduce symptoms in patients with IBS; a randomized, double-blinded, placebo-controlled study found that supplementation with 300 GalU alpha-galactosidase reduced symptoms associated with intake of high-GOS foods in GOS-sensitive IBS patients.
Trisaccharides in supplement or functional food contexts appear in several forms:
No universally established therapeutic dosage range for isolated raffinose or maltotriose as dietary supplements has been defined by any regulatory body. For 2′-FL, infant formula concentrations from clinical trials range from 0.2 to 1.0 g/L of formula. For broader oligosaccharide prebiotic use, human trials have used doses ranging from 2.5 g/d to 10 g/d.
The most consistently documented adverse effect of dietary trisaccharides — particularly raffinose and other RFOs — is gastrointestinal gas and discomfort. Raffinose cannot be digested by humans and monogastric animals; instead, it passes into the large intestine, where it is bacterially fermented, causing gas, bloating, and flatulence. Some legumes can produce up to 137 ml h⁻¹ of flatus, causing severe abdominal discomfort, bloating, belching, flatulence, constipation, and diarrhea. RFOs primarily cause flatulence in humans and animals; flatulence is the single most important factor that deters consumption and utilization of legumes in human and animal diets.
Humans and other monogastric animals find RFOs difficult to digest due to the absence of the enzyme required for their hydrolysis; food containing higher RFOs takes a shorter time to pass through the digestive tract, causing reduced absorption of beneficial nutrients. This effect is dose-dependent and can limit the bioavailability of minerals and other nutrients when large quantities of RFO-rich foods are consumed.
The digestive enzyme supplement alpha-galactosidase, which helps the breakdown of galacto-oligosaccharides (GOS), may reduce the gastrointestinal symptoms associated with raffinose and related compounds. When soy milk was fermented using the α-galactosidase-producing Lactobacillus fermentum CRL722 strain, the resulting product failed to induce H₂ emission in rats; when L. fermentum CRL722 was co-administered with native soy milk, a significant reduction (50%, P = 0.019) in H₂ emission was observed, showing that α-galactosidase from this strain remained active in situ in the gastrointestinal tract. This suggests that concurrent use of alpha-galactosidase supplements (such as the over-the-counter product Beano®) can meaningfully reduce the flatulence-inducing effects of raffinose-rich foods.
2′-FL possesses an exceptional safety profile, supported by its long history of safe consumption by breastfed infants, extensive toxicological testing in animals, and numerous human clinical trials in infants, children, and adults. Clinical experiences demonstrated that 2′-FL being added to infant formula was safe, well-tolerated, and absorbed and excreted with similar efficiency to 2′-FL in human milk.
Alpha-galactosidase — an enzyme used to counteract the gas-producing effects of dietary trisaccharides — is generally recognized as safe (GRAS) per the FDA. Raffinose itself, as a component of commonly consumed plant foods, is generally regarded as safe in normal dietary quantities. 2′-FL has received regulatory approval in several jurisdictions for use in infant formula and adult food supplements; however, the specific regulatory pathway and status varies by country and is subject to ongoing review.
Individuals with irritable bowel syndrome (IBS) and those following a low-FODMAP diet may be more sensitive to the gas-producing effects of raffinose and related galacto-oligosaccharides. Galacto-oligosaccharides (GOS) are classified among the five categories of FODMAPs — carbohydrates that are poorly absorbed in the small intestine and highly fermentable in the large intestine — along with lactose, fructose, fructans, and polyols. For such individuals, the fermentative burden of raffinose-containing supplements may exacerbate symptoms. While the metabolic process does not result in digestive discomfort or adverse symptoms for all consumers, it has been associated with undesirable results such as abdominal cramping and excessive flatulence in sensitive individuals.
Health conditions that Trisaccharide may help support.
Body systems that Trisaccharide may help support.
Go back